Guardian Pharmacy Services (GRDN)
Market Price (7/9/2026): $40.41 | Market Cap: $2.6 BilSector: Health Care | Industry: Health Care Facilities
Guardian Pharmacy Services (GRDN)
Market Price (7/9/2026): $40.41Market Cap: $2.6 BilSector: Health CareIndustry: Health Care Facilities
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Low stock price volatilityVol 12M is 42% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Health Data Analytics, Show more. | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 32x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 29x, P/EPrice/Earnings or Price/(Net Income) is 48x Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.2% Key risksGRDN key risks include [1] margin compression from inflation due to its inability to raise prices for customers whose reimbursements are dictated by the government and PBMs, Show more. |
| Low stock price volatilityVol 12M is 42% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Health Data Analytics, Show more. |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 32x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 29x, P/EPrice/Earnings or Price/(Net Income) is 48x |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.2% |
| Key risksGRDN key risks include [1] margin compression from inflation due to its inability to raise prices for customers whose reimbursements are dictated by the government and PBMs, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Guardian Pharmacy Services (GRDN) stock has gained about 5% since 3/31/2026 because of the following key factors:
1. Guardian Pharmacy Services reported stronger-than-expected financial results for fiscal Q1 2026 (ended March 31, 2026). The company's diluted earnings per share (EPS) of $0.29 surpassed the consensus estimate of $0.24 by $0.05. Additionally, quarterly revenue rose 2.2% year-over-year to $336.6 million, exceeding analyst estimates of $329.89 million. Net income increased to $13.5 million from $9.3 million in the prior-year period, and Adjusted EBITDA grew to $29.8 million, or 8.8% of revenue. This improved profitability was partly driven by lower drug acquisition costs, influenced by the Inflation Reduction Act, which led to an improved gross margin as the cost of goods sold fell to 77.3% of revenue.
2. The company raised its full-year 2026 guidance, boosting investor confidence. Following the strong Q1 2026 performance, Guardian Pharmacy Services updated its outlook for fiscal year 2026, raising its Adjusted EBITDA guidance to a range of $123 million to $127 million. Analyst consensus EPS estimates for fiscal year 2026 also saw an increase from US$0.957 to US$1.07.
Show more
Guardian Pharmacy Services (GRDN) stock has gained about 5% since 3/31/2026 because of the following key factors:
1. Guardian Pharmacy Services reported stronger-than-expected financial results for fiscal Q1 2026 (ended March 31, 2026). The company's diluted earnings per share (EPS) of $0.29 surpassed the consensus estimate of $0.24 by $0.05. Additionally, quarterly revenue rose 2.2% year-over-year to $336.6 million, exceeding analyst estimates of $329.89 million. Net income increased to $13.5 million from $9.3 million in the prior-year period, and Adjusted EBITDA grew to $29.8 million, or 8.8% of revenue. This improved profitability was partly driven by lower drug acquisition costs, influenced by the Inflation Reduction Act, which led to an improved gross margin as the cost of goods sold fell to 77.3% of revenue.
2. The company raised its full-year 2026 guidance, boosting investor confidence. Following the strong Q1 2026 performance, Guardian Pharmacy Services updated its outlook for fiscal year 2026, raising its Adjusted EBITDA guidance to a range of $123 million to $127 million. Analyst consensus EPS estimates for fiscal year 2026 also saw an increase from US$0.957 to US$1.07.
3. Positive analyst sentiment and upgraded ratings contributed to buying interest. As of July 6, 2026, Guardian Pharmacy Services holds a "Strong Buy" consensus rating from five analysts, with 60% recommending a Strong Buy and 40% recommending a Buy. This optimism was further reflected in increased price targets, with one notably rising by 8.9% to US$47.00. Investor optimism, fueled by these analyst endorsements and the company's robust growth outlook, drove the stock higher, including an 8.8% surge on June 29, 2026.
4. Strategic expansion through acquisitions broadened the company's market presence. Guardian Pharmacy Services announced an expansion of its Virginia footprint with the acquisition of Wellness Concepts, an LTC pharmacy in Grottoes, Virginia, on July 1, 2026. This acquisition increases the company's presence to three pharmacies in Virginia and demonstrates a disciplined acquisition strategy, which is often viewed favorably by investors as a driver of future growth.
Show less
Stock Movement Drivers
Fundamental Drivers
The 7.2% change in GRDN stock from 3/31/2026 to 7/8/2026 was primarily driven by a 7.3% change in the company's Net Income Margin (%).| (LTM values as of) | 3312026 | 7082026 | Change |
|---|---|---|---|
| Stock Price ($) | 37.66 | 40.39 | 7.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,449 | 1,456 | 0.5% |
| Net Income Margin (%) | 3.4% | 3.6% | 7.3% |
| P/E Multiple | 48.5 | 48.2 | -0.5% |
| Shares Outstanding (Mil) | 63 | 63 | 0.0% |
| Cumulative Contribution | 7.2% |
Market Drivers
3/31/2026 to 7/8/2026| Return | Correlation | |
|---|---|---|
| GRDN | 7.2% | |
| Market (SPY) | 14.6% | 6.9% |
| Sector (XLV) | 10.7% | 17.1% |
Fundamental Drivers
The 34.2% change in GRDN stock from 12/31/2025 to 7/8/2026 was primarily driven by a 25.9% change in the company's Net Income Margin (%).| (LTM values as of) | 12312025 | 7082026 | Change |
|---|---|---|---|
| Stock Price ($) | 30.09 | 40.39 | 34.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,390 | 1,456 | 4.8% |
| Net Income Margin (%) | 2.9% | 3.6% | 25.9% |
| P/E Multiple | 46.5 | 48.2 | 3.7% |
| Shares Outstanding (Mil) | 62 | 63 | -1.9% |
| Cumulative Contribution | 34.2% |
Market Drivers
12/31/2025 to 7/8/2026| Return | Correlation | |
|---|---|---|
| GRDN | 34.2% | |
| Market (SPY) | 9.6% | 16.6% |
| Sector (XLV) | 5.3% | 18.7% |
Fundamental Drivers
The 89.5% change in GRDN stock from 6/30/2025 to 7/8/2026 was primarily driven by a 56.5% change in the company's Net Income Margin (%).| (LTM values as of) | 6302025 | 7082026 | Change |
|---|---|---|---|
| Stock Price ($) | 21.31 | 40.39 | 89.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,073 | 1,456 | 35.7% |
| Net Income Margin (%) | 2.3% | 3.6% | 56.5% |
| P/E Multiple | 51.9 | 48.2 | -7.1% |
| Shares Outstanding (Mil) | 61 | 63 | -3.9% |
| Cumulative Contribution | 89.5% |
Market Drivers
6/30/2025 to 7/8/2026| Return | Correlation | |
|---|---|---|
| GRDN | 89.5% | |
| Market (SPY) | 21.7% | 21.5% |
| Sector (XLV) | 22.0% | 17.2% |
Fundamental Drivers
nullnull
Market Drivers
6/30/2023 to 7/8/2026| Return | Correlation | |
|---|---|---|
| GRDN | ||
| Market (SPY) | 74.1% | 25.5% |
| Sector (XLV) | 28.0% | 25.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| GRDN Return | - | - | - | 27% | 49% | 33% | 150% |
| Peers Return | 61% | -3% | 21% | 10% | 23% | 34% | 242% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 100% |
Monthly Win Rates [3] | |||||||
| GRDN Win Rate | - | - | - | 75% | 67% | 71% | |
| Peers Win Rate | 72% | 47% | 56% | 50% | 71% | 52% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 57% | |
Max Drawdowns [4] | |||||||
| GRDN Max Drawdown | - | - | - | - | -26% | -14% | |
| Peers Max Drawdown | -18% | -38% | -28% | -37% | -36% | -28% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ACHC, GMRS, PARK, HCA, THC.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/8/2026 (YTD)
How Low Can It Go
| Event | GRDN | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -12.4% | -18.8% |
| % Gain to Breakeven | 14.1% | 23.1% |
| Time to Breakeven | 12 days | 79 days |
In The Past
Guardian Pharmacy Services's stock fell -12.4% during the 2025 US Tariff Shock. Such a loss loss requires a 14.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
In The Past
Guardian Pharmacy Services's stock fell -12.4% during the 2025 US Tariff Shock. Such a loss loss requires a 14.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Guardian Pharmacy Services (GRDN)
Guardian Pharmacy Services (GRDN) is a leading pharmacy services company specializing in providing technology-enabled solutions to long-term health care facilities (LTCFs). Its core mission is to help residents of these facilities adhere to their appropriate drug regimens, which ultimately reduces healthcare costs and improves clinical outcomes. The company focuses on delivering high-touch, individualized drug dispensing and administration services, particularly tailored for historically lower acuity LTCFs such as assisted living facilities (ALFs) and behavioral health facilities and group homes (BHFs). These target markets represent over two-thirds of GRDN’s annual revenue, though it also serves skilled nursing facilities (SNFs).
GRDN differentiates itself by addressing the specific challenges faced by ALFs and BHFs, including residents having diverse pharmacy benefit plans, facilities often lacking on-site clinical staff, and residents' right to choose their pharmacy. As a trusted partner to residents, LTCFs, and health plan payors, Guardian offers an extensive suite of services. These include optimizing pharmacy benefit plan coverage, analyzing potential adverse drug interactions, providing robotic dispensing with customized compliance solutions, and integrating drug regimens with facilities' Electronic Medication Administration Records (EMARs). The company also trains LTCF caregivers, conducts compliance mock audits, and employs consulting pharmacists to periodically review resident drug regimens, all supported by proprietary data analytics systems to ensure precise medication delivery.
AI Analysis | Feedback
Here are 1-3 brief analogies to describe Guardian Pharmacy Services (GRDN):
- ADP for medication management in assisted living facilities.
- Salesforce for medication management in assisted living facilities.
- PillPack by Amazon Pharmacy for assisted living facilities.
AI Analysis | Feedback
- Medication Dispensing and Adherence Solutions: Provides robotic dispensing and customized medication packaging, integrated with Electronic Medication Administration Records (EMARs), to ensure residents receive their prescribed drugs accurately and on time.
- Clinical Pharmacy Consulting Services: Offers expert consultation including proactive analysis of potential adverse drug interactions and periodic review of resident drug regimens by consulting pharmacists.
- Pharmacy Benefit Plan Optimization: Assists residents in optimizing their pharmacy benefit plan coverage by coordinating formulary interchanges with their physicians.
- Caregiver Training and Education: Delivers training to long-term care facility caregivers to enhance their ability to administer medications safely, efficiently, and cost-effectively.
- Regulatory Compliance Support: Conducts mock audits for long-term care facilities to help monitor and ensure compliance with drug administration and government regulations.
AI Analysis | Feedback
Guardian Pharmacy Services (GRDN) sells primarily to individuals.
The company serves the following categories of customers:
- Residents of Assisted Living Facilities (ALFs)
- Residents of Behavioral Health Facilities and Group Homes (BHFs)
- Residents of Skilled Nursing Facilities (SNFs)
AI Analysis | Feedback
AI Analysis | Feedback
Fred Burke President & CEO
Fred Burke is the President, CEO, and Co-founder of Guardian Pharmacy Services, which he founded in 2004. Prior to Guardian, he co-founded Central Pharmacy Services, Inc. (CPSI) in 1992, a nuclear pharmacy company that grew to 45 business units and served over 1,000 hospitals and clinics across 22 states. CPSI was recognized on the Inc. 500 lists in 1997 and 1999, and was subsequently acquired by Cardinal Health in 2001. Burke also co-founded Sales Technologies, Inc. (ST) in 1983, a sales force automation company that achieved over 600 employees worldwide before its acquisition by The Dun & Bradstreet Corporation in 1989. His early career includes roles as a consultant with McKinsey & Company and a Brand Manager at Procter & Gamble. Guardian Pharmacy Services has been primarily capitalized by Bindley Capital Partners, LLC, and Cardinal Equity Partners has also made significant capital investments, indicating a pattern of managing companies backed by private equity firms.
David Morris EVP & CFO
David Morris is the EVP and CFO, and a Co-founder of Guardian Pharmacy Services. He served as CFO of Central Pharmacy Services (CPSI) from 1993 to 2001, joining shortly after its inception to build the central support and financial structure, and was part of the team when CPSI was acquired by Cardinal Health. Before that, Morris was the President of the PBM Division at Complete Health and worked as a Certified Public Accountant at Ernst & Young LLP. Guardian Pharmacy Services has been primarily capitalized by Bindley Capital Partners, LLC, and Cardinal Equity Partners has also made significant capital investments, indicating a pattern of managing companies backed by private equity firms.
Kendall Forbes EVP, Sales & Operations
Kendall Forbes is a Co-founder and EVP of Sales & Operations at Guardian Pharmacy Services. With over 35 years of experience, he played a key role in the growth of Guardian and its pharmacy partners. Prior to co-founding Guardian, Forbes was a co-founder and the Executive Vice President of Operations for Central Pharmacy Services (CPSI) from 1993 to 2004, which was acquired by Cardinal Health. He also previously owned Baton Rouge Central Pharmacy from 1985 to 1993. Guardian Pharmacy Services has been primarily capitalized by Bindley Capital Partners, LLC, and Cardinal Equity Partners has also made significant capital investments, indicating a pattern of managing companies backed by private equity firms.
AI Analysis | Feedback
1. Intense Competition and Resident Choice
Guardian Pharmacy Services operates in a highly competitive environment where residents in Assisted Living Facilities (ALFs) have the right to choose their own pharmacy. This often leads to multiple pharmacy service providers within a single ALF, requiring Guardian to continuously strive for "resident adoption" to acquire and retain customers, posing a risk of losing residents to competitors. [cite: background]
2. Reliance on Complex and Evolving Reimbursement Structures
The company navigates a complex landscape of varying pharmacy benefit plans, each with distinct formularies and reimbursement processes. Changes in these plans, formularies, or overall reimbursement policies by health plan payors could significantly impact Guardian's revenue and profitability. [cite: background]
3. Concentration in Assisted Living and Behavioral Health Markets
Over two-thirds of Guardian's annual revenue is generated from residents of Assisted Living Facilities (ALFs) and Behavioral Health Facilities (BHFs). This high concentration means the business is particularly vulnerable to adverse trends, regulatory changes, or shifts in growth potential within these specific long-term care sectors. [cite: background]
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
Share Repurchases
- Guardian Pharmacy Services announced a plan in May 2025 to buy back 1,457,365 shares in a private transaction, utilizing proceeds from a public offering.
- In 2025, the company completed a "synthetic secondary" transaction, repurchasing 1,440,447 outstanding shares of Class A Common Stock at $21.00 per share, amounting to approximately $30.25 million.
- The 2025 financial results reported repurchases of outstanding Class A common stock totaling $29.039 million.
Share Issuance
- Guardian Pharmacy Services, Inc. completed its Initial Public Offering (IPO) on September 25, 2024, issuing 8,000,000 shares of Class A common stock at $14.00 per share, raising $112 million.
- In May 2025, as part of a non-dilutive "synthetic secondary" transaction, the company issued 1,440,447 new shares of Class A common stock, with the net proceeds used to repurchase an equal number of shares.
- Following the IPO, the company anticipated granting equity awards, including stock options with an aggregate award value of $10.0 million and restricted stock units valued at $9.0 million starting in 2025.
Inbound Investments
- Prior to its IPO, Cardinal Equity Partners, along with founders Fred Burke, David Morris, and Kendall Forbes, made significant capital investments in Guardian.
- As of December 31, 2025, Brown Advisory Inc and its affiliated entities reported a 4.54% beneficial ownership stake in Guardian Pharmacy Services, comprising 1,644,569 shares of Class A common stock.
Outbound Investments
- In the first quarter of 2025, Guardian Pharmacy Services acquired Senior Care Pharmacy in Wichita, Kansas, as part of its growth strategy.
- During the fourth quarter of 2025, the company acquired North Ridge Pharmacy in Missoula, Montana, increasing its total number of full-service pharmacies to 54.
Capital Expenditures
- Guardian Pharmacy Services has demonstrated significant reinvestment in its business, with its return on capital employed increasing to 27% over the last five years and 82% more capital being utilized.
- The company's financial reporting indicates that Adjusted EBITDA does not account for cash capital expenditure requirements related to asset replacements or new capital investments, suggesting ongoing capital expenditure needs for operational maintenance and growth.
- While specific dollar values for general capital expenditures are not detailed in available reports, the acquisitions of Senior Care Pharmacy in Q1 2025 and North Ridge Pharmacy in Q4 2025 represent significant capital deployment for expanding its pharmacy network.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 35.56 |
| Mkt Cap | 10.3 |
| Rev LTM | 12,620 |
| Op Inc LTM | 2,113 |
| FCF LTM | 1,710 |
| FCF 3Y Avg | 1,114 |
| CFO LTM | 2,274 |
| CFO 3Y Avg | 1,649 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.8% |
| Rev Chg 3Y Avg | 7.8% |
| Rev Chg Q | 5.9% |
| QoQ Delta Rev Chg LTM | 1.4% |
| Op Inc Chg LTM | 17.8% |
| Op Inc Chg 3Y Avg | 13.5% |
| Op Mgn LTM | 13.7% |
| Op Mgn 3Y Avg | 14.9% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 11.6% |
| CFO/Rev 3Y Avg | 11.1% |
| FCF/Rev LTM | 7.6% |
| FCF/Rev 3Y Avg | 6.4% |
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| ANDA216149 | ESOMEPRAZOLE MAGNESIUM | esomeprazole magnesium | capsule, delayed release | 3152023 | |||||
| ANDA214541 | LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE | loperamide hydrochloride | tablet | 5272021 | |||||
| ANDA210755 | IBUPROFEN | ibuprofen | suspension/drops | 9262018 | |||||
| ANDA210149 | IBUPROFEN | ibuprofen | suspension | 8172018 | |||||
| ANDA209215 | GUAIFENESIN | guaifenesin | tablet, extended release | 9062017 | |||||
| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| ANDA216149 | ESOMEPRAZOLE MAGNESIUM | esomeprazole magnesium | capsule, delayed release | 3152023 | |||||
| ANDA214541 | LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE | loperamide hydrochloride | tablet | 5272021 | |||||
| ANDA210755 | IBUPROFEN | ibuprofen | suspension/drops | 9262018 | |||||
| ANDA210149 | IBUPROFEN | ibuprofen | suspension | 8172018 | |||||
| ANDA209215 | GUAIFENESIN | guaifenesin | tablet, extended release | 9062017 | |||||
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Sales of pharmaceutical and medical products | 1,449 | 1,228 | 1,046 | 909 | 792 |
| Total | 1,449 | 1,228 | 1,046 | 909 | 792 |
| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Sales of pharmaceutical and medical products | 49 | -71 | 38 |
| Total | 49 | -71 | 38 |
| $ Mil | 2024 |
|---|---|
| Sales of pharmaceutical and medical products | 321 |
| Total | 321 |
Price Behavior
| Market Price | $40.39 | |
| Market Cap ($ Bil) | 2.6 | |
| First Trading Date | 09/26/2024 | |
| Distance from 52W High | -6.9% | |
| 50 Days | 200 Days | |
| DMA Price | $38.85 | $32.28 |
| DMA Trend | up | up |
| Distance from DMA | 4.0% | 25.1% |
| 3M | 1YR | |
| Volatility | 37.6% | 42.1% |
| Downside Capture | 63.52 | 59.48 |
| Upside Capture | 42.18 | 123.75 |
| Correlation (SPY) | 7.8% | 22.3% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.05 | 0.11 | 0.20 | 0.52 | 0.72 | -0.13 |
| Up Beta | -1.10 | -0.81 | -0.29 | 0.10 | 0.63 | -0.38 |
| Down Beta | 0.90 | 0.12 | -0.11 | 0.19 | 0.44 | -0.40 |
| Up Capture | 58% | 77% | 59% | 110% | 131% | 44% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 12 | 23 | 35 | 68 | 138 | 238 |
| Down Capture | -32% | 6% | 55% | 57% | 61% | 73% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 9 | 18 | 28 | 57 | 113 | 199 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GRDN | |
|---|---|---|---|---|
| GRDN | 95.3% | 42.0% | 1.70 | - |
| Sector ETF (XLV) | 22.5% | 15.7% | 1.09 | 16.8% |
| Equity (SPY) | 21.2% | 12.5% | 1.26 | 22.0% |
| Gold (GLD) | 21.9% | 27.8% | 0.70 | 3.9% |
| Commodities (DBC) | 25.0% | 18.7% | 1.06 | -9.5% |
| Real Estate (VNQ) | 12.7% | 13.9% | 0.62 | 5.8% |
| Bitcoin (BTCUSD) | -41.4% | 42.8% | -1.13 | 6.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GRDN | |
|---|---|---|---|---|
| GRDN | 20.2% | 47.9% | 1.25 | - |
| Sector ETF (XLV) | 6.8% | 14.9% | 0.27 | 25.0% |
| Equity (SPY) | 13.2% | 17.1% | 0.60 | 25.6% |
| Gold (GLD) | 17.8% | 18.3% | 0.79 | 3.3% |
| Commodities (DBC) | 7.8% | 19.5% | 0.30 | -8.4% |
| Real Estate (VNQ) | 2.8% | 18.9% | 0.05 | 18.9% |
| Bitcoin (BTCUSD) | 12.1% | 53.5% | 0.41 | 6.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GRDN | |
|---|---|---|---|---|
| GRDN | 9.6% | 47.9% | 1.25 | - |
| Sector ETF (XLV) | 10.9% | 16.6% | 0.54 | 25.0% |
| Equity (SPY) | 15.9% | 17.9% | 0.76 | 25.6% |
| Gold (GLD) | 11.5% | 16.1% | 0.58 | 3.3% |
| Commodities (DBC) | 6.4% | 18.0% | 0.28 | -8.4% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.22 | 18.9% |
| Bitcoin (BTCUSD) | 58.0% | 66.2% | 0.98 | 6.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/9/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/6/2026 | -0.8% | -2.5% | 10.7% |
| 3/11/2026 | -0.7% | 1.2% | 16.8% |
| 1/13/2026 | -3.6% | -6.1% | 6.0% |
| 11/10/2025 | 5.0% | -4.8% | 4.8% |
| 8/11/2025 | 13.8% | 24.8% | 45.8% |
| 5/12/2025 | -4.0% | 3.4% | -21.4% |
| 3/26/2025 | 4.3% | 6.4% | 19.6% |
| 11/12/2024 | -10.7% | -2.8% | 13.5% |
| SUMMARY STATS | |||
| # Positive | 3 | 4 | 7 |
| # Negative | 5 | 4 | 1 |
| Median Positive | 5.0% | 4.9% | 13.5% |
| Median Negative | -3.6% | -3.8% | -21.4% |
| Max Positive | 13.8% | 24.8% | 45.8% |
| Max Negative | -10.7% | -6.1% | -21.4% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/6/2026 | -0.8% | -2.5% | 10.7% |
| 3/11/2026 | -0.7% | 1.2% | 16.8% |
| 1/13/2026 | -3.6% | -6.1% | 6.0% |
| 11/10/2025 | 5.0% | -4.8% | 4.8% |
| 8/11/2025 | 13.8% | 24.8% | 45.8% |
| 5/12/2025 | -4.0% | 3.4% | -21.4% |
| 3/26/2025 | 4.3% | 6.4% | 19.6% |
| 11/12/2024 | -10.7% | -2.8% | 13.5% |
| SUMMARY STATS | |||
| # Positive | 3 | 4 | 7 |
| # Negative | 5 | 4 | 1 |
| Median Positive | 5.0% | 4.9% | 13.5% |
| Median Negative | -3.6% | -3.8% | -21.4% |
| Max Positive | 13.8% | 24.8% | 45.8% |
| Max Negative | -10.7% | -6.1% | -21.4% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 03/11/2026 | 10-K |
| 09/30/2025 | 11/10/2025 | 10-Q |
| 06/30/2025 | 08/11/2025 | 10-Q |
| 03/31/2025 | 05/12/2025 | 10-Q |
| 12/31/2024 | 03/26/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 09/16/2024 | 424A |
| 06/30/2023 | 10/03/2023 | S-1 |
| 03/31/2023 | 07/12/2023 | DRS/A |
| 09/30/2021 | 11/22/2021 | DRS/A |
| 03/31/2021 | 07/23/2021 | DRS/A |
| 12/31/2019 | 04/03/2020 | DRS/A |
| 09/30/2019 | 02/13/2020 | DRS |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 03/11/2026 | 10-K |
| 09/30/2025 | 11/10/2025 | 10-Q |
| 06/30/2025 | 08/11/2025 | 10-Q |
| 03/31/2025 | 05/12/2025 | 10-Q |
| 12/31/2024 | 03/26/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 09/16/2024 | 424A |
| 06/30/2023 | 10/03/2023 | S-1 |
| 03/31/2023 | 07/12/2023 | DRS/A |
| 09/30/2021 | 11/22/2021 | DRS/A |
| 03/31/2021 | 07/23/2021 | DRS/A |
| 12/31/2019 | 04/03/2020 | DRS/A |
| 09/30/2019 | 02/13/2020 | DRS |
Recent Forward Guidance
Updated 6/1/2026Latest: Q1 2026 Earnings Reported 5/6/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 1.40 Bil | 1.41 Bil | 1.42 Bil | 0 | Affirmed | Guidance: 1.41 Bil for 2026 | |
| 2026 Adjusted EBITDA | 123.00 Mil | 125.00 Mil | 127.00 Mil | 2.5% | Raised | Guidance: 122.00 Mil for 2026 | |
Prior: Q4 2025 Earnings Reported 3/11/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 1.40 Bil | 1.41 Bil | 1.42 Bil | 0 | Affirmed | Guidance: 1.41 Bil for 2026 | |
| 2026 Adjusted EBITDA | 120.00 Mil | 122.00 Mil | 124.00 Mil | 4.7% | Raised | Guidance: 116.50 Mil for 2026 | |
Q4 2025 Earnings Reported 1/13/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Revenue | 1.43 Bil | 1.44 Bil | 1.45 Bil | 0 | Affirmed | Guidance: 1.44 Bil for 2025 | |
| 2025 Adjusted EBITDA | 104.00 Mil | 105.00 Mil | 106.00 Mil | 0 | Affirmed | Guidance: 105.00 Mil for 2025 | |
| 2026 Revenue | 1.40 Bil | 1.41 Bil | 1.42 Bil | -2.1% | Lower New | Actual: 1.44 Bil for 2025 | |
| 2026 Adjusted EBITDA | 115.00 Mil | 116.50 Mil | 118.00 Mil | 11.0% | Higher New | Actual: 105.00 Mil for 2025 | |
Q3 2025 Earnings Reported 11/10/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Revenue | 1.43 Bil | 1.44 Bil | 1.45 Bil | 2.9% | Raised | Guidance: 1.40 Bil for 2025 | |
| 2025 Adjusted EBITDA | 104.00 Mil | 105.00 Mil | 106.00 Mil | 4.0% | Raised | Guidance: 101.00 Mil for 2025 | |
Insider Activity
Updated 4/26/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Pharmacy, Investors, Llc | Direct | Sell | 3242026 | 29.68 | 827,636 | 24,566,306 | 30,748,933 | Form | |
| 2 | Morris, David K | See Remarks | Direct | Sell | 3242026 | 29.68 | 187,855 | 5,576,006 | 7,553,365 | Form |
| 3 | Burke, Fred | See Remarks | Direct | Sell | 3242026 | 29.68 | 671,432 | 19,929,780 | 24,945,559 | Form |
| 4 | Forbes, Kendall | See Remarks | Direct | Sell | 3242026 | 29.68 | 346,672 | 10,290,092 | 13,453,771 | Form |
| 5 | Cardinal, Equity Fund, LP | Direct | Sell | 3242026 | 29.68 | 275,728 | 8,184,296 | 10,244,113 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Pharmacy, Investors, Llc | Direct | Sell | 3242026 | 29.68 | 827,636 | 24,566,306 | 30,748,933 | Form | |
| 2 | Morris, David K | See Remarks | Direct | Sell | 3242026 | 29.68 | 187,855 | 5,576,006 | 7,553,365 | Form |
| 3 | Burke, Fred | See Remarks | Direct | Sell | 3242026 | 29.68 | 671,432 | 19,929,780 | 24,945,559 | Form |
| 4 | Forbes, Kendall | See Remarks | Direct | Sell | 3242026 | 29.68 | 346,672 | 10,290,092 | 13,453,771 | Form |
| 5 | Cardinal, Equity Fund, LP | Direct | Sell | 3242026 | 29.68 | 275,728 | 8,184,296 | 10,244,113 | Form | |
| 6 | Salentine, Thomas J JR | Bindley Capital Partners I, LLC | Sell | 3242026 | 29.68 | 3,570,677 | 105,986,620 | 132,660,472 | Form | |
| 7 | Bindley, Capital Partners I, Llc | Direct | Sell | 3242026 | 29.68 | 3,570,677 | 105,986,620 | 132,660,472 | Form | |
| 8 | Ackerman, John | Pharmacy Investors, LLC | Sell | 3242026 | 29.68 | 827,636 | 24,566,306 | 30,748,933 | Form | |
| 9 | Ackerman, John | Cardinal Equity Fund, L.P. | Sell | 3242026 | 29.68 | 275,728 | 8,184,296 | 10,244,113 | Form | |
| 10 | Bindley, William E | Bindley Capital Partners I, LLC | Sell | 3242026 | 29.68 | 3,570,677 | 105,986,620 | 132,660,472 | Form | |
| 11 | Cosler, Steven D | Direct | Buy | 12052025 | 29.61 | 3,370 | 99,786 | 739,776 | Form | |
| 12 | Cardinal, Equity Fund, LP | Direct | Sell | 9302025 | 20.16 | 50,305 | 1,014,149 | 3,019,847 | Form | |
| 13 | Pharmacy, Investors, Llc | Direct | Sell | 9302025 | 20.16 | 150,998 | 3,044,120 | 9,064,420 | Form | |
| 14 | Cardinal, Equity Fund, LP | Direct | Sell | 9302025 | 20.16 | 270,958 | 5,462,513 | 4,033,996 | Form | |
| 15 | Pharmacy, Investors, Llc | Direct | Sell | 9302025 | 20.16 | 813,318 | 16,396,491 | 12,108,540 | Form | |
| 16 | Bindley, William E | Bindley Capital Partners I, LLC | Sell | 5292025 | 20.16 | 651,454 | 13,133,313 | 39,106,711 | Form | |
| 17 | Salentine, Thomas J JR | Bindley Capital Partners I, LLC | Sell | 5292025 | 20.16 | 651,454 | 13,133,313 | 39,106,711 | Form | |
| 18 | Ackerman, John | Pharmacy Investors, LLC | Sell | 5292025 | 20.16 | 150,998 | 3,044,120 | 9,064,420 | Form | |
| 19 | Ackerman, John | Cardinal Equity Fund, L.P. | Sell | 5292025 | 20.16 | 50,305 | 1,014,149 | 3,019,847 | Form | |
| 20 | Morris, David K | See Remarks | Direct | Sell | 5292025 | 20.16 | 68,547 | 1,381,908 | 4,324,219 | Form |
| 21 | Burke, Fred | See Remarks | Direct | Sell | 5292025 | 20.16 | 138,705 | 2,796,293 | 8,326,463 | Form |
| 22 | Forbes, Kendall | See Remarks | Direct | Sell | 5292025 | 20.16 | 64,991 | 1,310,219 | 4,110,745 | Form |
| 23 | Bindley, Capital Partners I, Llc | Direct | Sell | 5292025 | 20.16 | 651,454 | 13,133,313 | 39,106,711 | Form | |
| 24 | Bindley, William E | Bindley Capital Partners I, LLC | Sell | 5292025 | 20.16 | 3,508,905 | 70,739,525 | 52,240,023 | Form | |
| 25 | Salentine, Thomas J JR | Bindley Capital Partners I, LLC | Sell | 5292025 | 20.16 | 3,508,905 | 70,739,525 | 52,240,023 | Form | |
| 26 | Ackerman, John | Pharmacy Investors, LLC | Sell | 5292025 | 20.16 | 813,318 | 16,396,491 | 12,108,540 | Form | |
| 27 | Ackerman, John | Cardinal Equity Fund, L.P. | Sell | 5292025 | 20.16 | 270,958 | 5,462,513 | 4,033,996 | Form | |
| 28 | Morris, David K | See Remarks | Direct | Sell | 5292025 | 20.16 | 369,212 | 7,443,314 | 5,706,127 | Form |
| 29 | Burke, Fred | See Remarks | Direct | Sell | 5292025 | 20.16 | 747,102 | 15,061,576 | 11,122,756 | Form |
| 30 | Forbes, Kendall | See Remarks | Direct | Sell | 5292025 | 20.16 | 350,058 | 7,057,169 | 5,420,964 | Form |
| 31 | Bindley, Capital Partners I, Llc | Direct | Sell | 5292025 | 20.16 | 3,508,905 | 70,739,525 | 52,240,023 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.